<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-74657" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Aromatase Inhibitors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Peters</surname>
            <given-names>Azabelle</given-names>
          </name>
          <aff>Lincoln Memorial University, DeBusk College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Azabelle Peters declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-74657.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Anastrozole is a medication used in the management and treatment of breast cancer. It is in the aromatase inhibitors class of drugs. This activity describes the indications, action, and contraindications for anastrozole as a valuable agent in managing advanced hormone-receptive breast cancer. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the management of patients with breast cancer and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of aromatase inhibitors.</p></list-item><list-item><p>Summarize the potential adverse reactions and contraindications of aromatase inhibitor use.</p></list-item><list-item><p>Review the indicated uses for aromatase inhibitors in current medical practice.</p></list-item><list-item><p>Outline the importance of improving care coordination amongst interprofessional team members to improve health care outcomes for patients affected by breast cancer and other conditions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=74657&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=74657">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-74657.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Aromatase inhibitors (AIs) are indicated in the treatment of hormone-receptive breast cancer in postmenopausal women in various settings. Studies have shown that they are effective when used as&#x000a0;adjuvant therapy to chemotherapy and surgery in metastatic estrogen-dependent breast cancer. Their use in preventative and adjuvant therapies for other conditions is currently under investigation.<xref ref-type="bibr" rid="article-74657.r1">[1]</xref><xref ref-type="bibr" rid="article-74657.r2">[2]</xref></p>
        <p>
<bold>FDA Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer<xref ref-type="bibr" rid="article-74657.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer<xref ref-type="bibr" rid="article-74657.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Second-line treatment of advanced breast cancer that has progressed on Tamoxifen therapy<xref ref-type="bibr" rid="article-74657.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of male gynecomastia<xref ref-type="bibr" rid="article-74657.r6">[6]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Second-line treatment for the prevention of hormone-receptor-positive breast cancer<xref ref-type="bibr" rid="article-74657.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>FDA Non-approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of benign conditions like cyclical breast pain and recurrent fibrocystic disease<xref ref-type="bibr" rid="article-74657.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of symptomatic myomas and endometriosis as an alternative to surgical intervention&#x000a0;<xref ref-type="bibr" rid="article-74657.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Ovulation induction in the treatment of infertility<xref ref-type="bibr" rid="article-74657.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of male breast cancer<xref ref-type="bibr" rid="article-74657.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of prostate cancer<xref ref-type="bibr" rid="article-74657.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of late-onset hypogonadism or partial androgen deficiency, obesity-related hypogonadotropic hypogonadism, and male subfertility<xref ref-type="bibr" rid="article-74657.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of rare pediatric conditions associated with sex steroid excess<xref ref-type="bibr" rid="article-74657.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of boys with short stature and constitutional delay of puberty<xref ref-type="bibr" rid="article-74657.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Prevention of the initial estrogen flare effect of gonadotropin-releasing hormone agonist treatment<xref ref-type="bibr" rid="article-74657.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-74657.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Aromatase inhibitors (AIs) inhibit the action of the enzyme aromatase. Aromatase&#x000a0;(estrogen synthetase) is a member of the cytochrome P450 superfamily of monooxygenases and catalyzes the demethylation of androgens' carbon 19, producing phenolic 18-carbon estrogens.<xref ref-type="bibr" rid="article-74657.r13">[13]</xref>&#x000a0;In postmenopausal women, the conversion of androgens to estrogens via this pathway in the adrenal glands, the skin, the muscle, and the adipose tissue, is the primary source of estrogen. Aromatase inhibitors block this pathway and consequently suppress estrogen levels in postmenopausal women. The breast cancer cells also demonstrate aromatase activity, a likely source of local estrogen for the tumor cells.&#x000a0;The inhibition or inactivation of aromatase suppresses serum estrogen levels, which decrease estrogen-mediated cancer cell proliferation in hormone receptor-positive breast cancer.<xref ref-type="bibr" rid="article-74657.r14">[14]</xref></p>
        <p>In premenopausal women, AIs induce an increase in gonadotropin secretion secondary to the reduced negative feedback of estrogen to the pituitary, resulting in ovarian stimulation. Clinicians can use AIs to induce ovulation in the treatment of infertility.<xref ref-type="bibr" rid="article-74657.r15">[15]</xref><xref ref-type="bibr" rid="article-74657.r14">[14]</xref>&#x000a0;Aromatase activity increases in endometriosis with&#x000a0;extrauterine endometrial tissue acting as a source of estrogens. Estrogen stimulates the synthesis of PGE2, which causes increased aromatase activity in the endometrium. This vicious cycle leads to the growth of ectopic endometrial tissue, which is blocked by aromatase inhibitors by inhibiting the synthesis of estrogen in&#x000a0;extrauterine endometrial tissue.<xref ref-type="bibr" rid="article-74657.r16">[16]</xref><xref ref-type="bibr" rid="article-74657.r17">[17]</xref></p>
        <p>In men, estrogen excess shows an association with premature closure of the epiphyses. Aromatase inhibitors decrease estrogen by inhibiting the conversion of testosterone to estrogen and have therefore been used in patients with&#x000a0;short stature and/or constitutional delay of puberty. Lowering estrogen levels is associated with an increase in LH, FSH, and testosterone. Therefore aromatase inhibitors have also been used in&#x000a0;late-onset hypogonadism or partial androgen deficiency.&#x000a0;In obese men, there is an increased conversion of androgens to estrogen in the adipose tissue, leading to increased estrogen levels. Aromatase inhibitors also decrease this conversion causing decreased estrogen and increased testosterone and FSH in men with obesity-related hypogonadotropic hypogonadism&#x000a0;and male subfertility.<xref ref-type="bibr" rid="article-74657.r18">[18]</xref></p>
      </sec>
      <sec id="article-74657.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Anastrozole, a selective aromatase inhibitor, is available as a 1 mg tablet, which is&#x000a0;to be taken&#x000a0;orally once a day, with or without food.&#x000a0;No dose adjustment is necessary&#x000a0;for patients with renal or liver impairment or elderly patients.&#x000a0;The American Society of Clinical Oncology recommends the use of aromatase inhibitors as a component of adjuvant hormonal therapy after surgery for ten years in postmenopausal patients who have a diagnosis of early-stage, node-positive, and hormone receptive breast cancer.</p>
        <p>Letrozole is also a selective aromatase inhibitor. It is manufactured in 2.5 mg tablets. For postmenopausal breast cancer, dosing is 2.5 mg daily. As an&#x000a0;agent to induce ovulation, dosing is 2.5 mg to 5 mg daily for 5 days starting on day 3 of the menstrual cycle. Renal adjustment is unnecessary if creatinine clearance is above 10. In patients with cirrhosis of the liver, CHild-Pugh Class C, increase the dosing interval to every 48 hours.</p>
        <p>Exemestane, another selective agent, comes in 25 mg tablets, and for postmenopausal breast cancer, dosing is 25 mg daily for 2 to 3 years. No renal or hepatic dose adjustments are necessary.</p>
      </sec>
      <sec id="article-74657.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Various adverse reactions can happen with aromatase inhibitors. (Seen in less than 1 in 10,000 patients). Some of them are&#x000a0;as follows:</p>
        <list list-type="order">
          <list-item>
            <p>Ulcers and blisters are the common skin manifestations;</p>
          </list-item>
          <list-item>
            <p>Allergic reactions, such as swelling of the face along with lips&#x000a0;and tongue and occasionally throat; these reactions can result in difficulty swallowing and/or breathing;</p>
          </list-item>
          <list-item>
            <p>Liver function abnormality with or without jaundice due to inflammation of the liver;</p>
          </list-item>
          <list-item>
            <p>Bone loss due to estrogen deficiency with long-term use.</p>
          </list-item>
        </list>
        <p>Common adverse reactions (10% incidence) include the following: hot flashes, asthenia, joint disorders such as arthritis or arthralgia, osteoporosis, fractures, bone pain, back pain, vaginal dryness, dyspareunia, sexual dysfunction, uterine atrophy, hypertension, hyperlipidemia, hypercholesterolemia, thromboembolic disease, cardiac and cerebrovascular events, insomnia, nausea.<xref ref-type="bibr" rid="article-74657.r19">[19]</xref><xref ref-type="bibr" rid="article-74657.r20">[20]</xref><xref ref-type="bibr" rid="article-74657.r21">[21]</xref><xref ref-type="bibr" rid="article-74657.r22">[22]</xref><xref ref-type="bibr" rid="article-74657.r14">[14]</xref></p>
        <p>The most common reason for discontinuing aromatase inhibitor therapy is the development of arthralgias, known as aromatase inhibitor-associated arthralgia syndrome. Patients will present with joint pain and mild swelling in the absence of other systemic diseases or other causes. The deficiency of estrogen causes a decrease in bone mineral density, which contributes to joint pain. Estrogen also shows links to the regulation of cytokine activity as well as the modulation of pain reception in the nervous system.<xref ref-type="bibr" rid="article-74657.r23">[23]</xref></p>
      </sec>
      <sec id="article-74657.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are two major contraindications to aromatase inhibitors.</p>
        <list list-type="order">
          <list-item>
            <p>Hypersensitivity: Aromatase inhibitors are contraindicated in patients with hypersensitivity reactions to AI. Hypersensitivity can present as anaphylaxis, angioedema, and urticaria.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pregnancy and Premenopausal women: Aromatase inhibitors can harm the fetus or cause loss of pregnancy&#x000a0;in pregnant patients.<xref ref-type="bibr" rid="article-74657.r24">[24]</xref>&#x000a0;Due to their mechanism of action, AIs have no clinical benefit in breast cancer patients who are premenopausal.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-74657.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>All patients on aromatase inhibitors should have initial routine lab work, including a complete blood count, serum calcium, vitamin D levels, lipid profile, and liver function tests.<xref ref-type="bibr" rid="article-74657.r25">[25]</xref><xref ref-type="bibr" rid="article-74657.r26">[26]</xref>&#x000a0;Patients should also have a baseline bone mineral density test (DEXA scan) before initiating the treatment.<xref ref-type="bibr" rid="article-74657.r27">[27]</xref><xref ref-type="bibr" rid="article-74657.r14">[14]</xref></p>
      </sec>
      <sec id="article-74657.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Clinical trials have shown aromatase inhibitors were well tolerated, even at high doses.<xref ref-type="bibr" rid="article-74657.r27">[27]</xref>&#x000a0;There is no established dose of aromatase inhibitors considered life-threatening. There is no specific&#x000a0;treatment for the overdose of this class of medications. Standard treatment of care, such as frequent vital sign checks, induced emesis, and management of symptoms, is recommended.&#x000a0;</p>
      </sec>
      <sec id="article-74657.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interprofessional communication between healthcare teams is essential, especially in the management of cancer patients. Every professional has a vital role to play. Oncologists should select the treatment regimen based on the guidelines after thoroughly assessing the patient factors. For example, in hormone receptor-negative breast cancer or premenopausal patients with breast cancer, aromatase inhibitors may not be appropriate. Clinicians and nurses should be concerned enough about the adverse effects of long-term therapy with aromatase inhibitors, especially osteoporosis and hyperlipidemia. Pharmacists should evaluate the patient's medication history to prevent any drug interactions, especially with tamoxifen and warfarin. Nursing will provide patient counseling on the medication, answer patient questions, and serve as a contact point for patients and other interprofessional team members. Case management should include counseling regarding improving bone health and early initiation of bisphosphonates in the case of osteopenia. Utilizing these interprofessional strategies when using aromatase inhibitor therapy will lead to improved therapeutic patient results with fewer adverse events. [Level&#x000a0;5]</p>
      </sec>
      <sec id="article-74657.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=74657&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=74657">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/74657/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=74657">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-74657.s11">
        <title>References</title>
        <ref id="article-74657.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arora</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Potter</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>611</fpage>
            <page-range>611-6</page-range>
            <pub-id pub-id-type="pmid">15066080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brueggemeier</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Hackett</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Diaz-Cruz</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Aromatase inhibitors in the treatment of breast cancer.</article-title>
            <source>Endocr Rev</source>
            <year>2005</year>
            <month>May</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>331</fpage>
            <page-range>331-45</page-range>
            <pub-id pub-id-type="pmid">15814851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burstein</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Temin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Buchholz</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Gelmon</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hudis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Rowden</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Solky</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Stearns</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Winer</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Griggs</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Jul</month>
            <day>20</day>
            <volume>32</volume>
            <issue>21</issue>
            <fpage>2255</fpage>
            <page-range>2255-69</page-range>
            <pub-id pub-id-type="pmid">24868023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paridaens</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Dirix</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Beex</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Nooij</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Cufer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Piccart</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bogaerts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Therasse</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Oct</month>
            <day>20</day>
            <volume>26</volume>
            <issue>30</issue>
            <fpage>4883</fpage>
            <page-range>4883-90</page-range>
            <pub-id pub-id-type="pmid">18794551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simpson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Letrozole: a review of its use in postmenopausal women with breast cancer.</article-title>
            <source>Drugs</source>
            <year>2004</year>
            <volume>64</volume>
            <issue>11</issue>
            <fpage>1213</fpage>
            <page-range>1213-30</page-range>
            <pub-id pub-id-type="pmid">15161328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The therapeutic potential of aromatase inhibitors.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>337</fpage>
            <page-range>337-51</page-range>
            <pub-id pub-id-type="pmid">12605559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behan</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Amir</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Casper</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Aromatase inhibitors for prevention of breast cancer in postmenopausal women: a narrative review.</article-title>
            <source>Menopause</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>342</fpage>
            <page-range>342-50</page-range>
            <pub-id pub-id-type="pmid">25692874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bedaiwy</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mousa</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Casper</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Aromatase inhibitors: potential reproductive implications.</article-title>
            <source>J Minim Invasive Gynecol</source>
            <year>2009</year>
            <season>Sep-Oct</season>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>533</fpage>
            <page-range>533-9</page-range>
            <pub-id pub-id-type="pmid">19608462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santen</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of aromatase: insights from recent studies.</article-title>
            <source>Steroids</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>68</volume>
            <issue>7-8</issue>
            <fpage>559</fpage>
            <page-range>559-67</page-range>
            <pub-id pub-id-type="pmid">12957661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zagouri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sergentanis</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Azim</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Chrysikos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dimopoulos</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Psaltopoulou</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Aromatase inhibitors in male breast cancer: a pooled analysis.</article-title>
            <source>Breast Cancer Res Treat</source>
            <year>2015</year>
            <month>May</month>
            <volume>151</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-7</page-range>
            <pub-id pub-id-type="pmid">25850534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Guay</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical Use of Aromatase Inhibitors in Adult Males.</article-title>
            <source>Sex Med Rev</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <page-range>79-90</page-range>
            <pub-id pub-id-type="pmid">27784593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hero</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Aromatase Inhibitors in the Treatment of Short Stature.</article-title>
            <source>Endocr Dev</source>
            <year>2016</year>
            <volume>30</volume>
            <fpage>130</fpage>
            <page-range>130-40</page-range>
            <pub-id pub-id-type="pmid">26684331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blakemore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Naftolin</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Aromatase: Contributions to Physiology and Disease in Women and Men.</article-title>
            <source>Physiology (Bethesda)</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>258</fpage>
            <page-range>258-69</page-range>
            <pub-id pub-id-type="pmid">27252161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nabholtz</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Long-term safety of aromatase inhibitors in the treatment of breast cancer.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>189</fpage>
            <page-range>189-204</page-range>
            <pub-id pub-id-type="pmid">18728707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forbes</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.</article-title>
            <source>Semin Oncol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>2 Suppl 7</issue>
            <fpage>S2</fpage>
            <page-range>S2-7</page-range>
            <pub-id pub-id-type="pmid">16730270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x00142;opie&#x00144;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>M&#x00119;czekalski</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Aromatase inhibitors in the treatment of endometriosis.</article-title>
            <source>Prz Menopauzalny</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-7</page-range>
            <pub-id pub-id-type="pmid">27095958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu Hashim</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Potential role of aromatase inhibitors in the treatment of endometriosis.</article-title>
            <source>Int J Womens Health</source>
            <year>2014</year>
            <volume>6</volume>
            <fpage>671</fpage>
            <page-range>671-80</page-range>
            <pub-id pub-id-type="pmid">25092998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Ronde</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Aromatase inhibitors in men: effects and therapeutic options.</article-title>
            <source>Reprod Biol Endocrinol</source>
            <year>2011</year>
            <month>Jun</month>
            <day>21</day>
            <volume>9</volume>
            <fpage>93</fpage>
            <pub-id pub-id-type="pmid">21693046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuzick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sestak</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buzdar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dowsett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Forbes</surname>
                <given-names>JF</given-names>
              </name>
              <collab>ATAC/LATTE investigators</collab>
            </person-group>
            <article-title>Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>1135</fpage>
            <page-range>1135-41</page-range>
            <pub-id pub-id-type="pmid">21087898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Botticelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lunardi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marchetti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.</article-title>
            <source>Pharmacogenomics</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>821</fpage>
            <page-range>821-830</page-range>
            <pub-id pub-id-type="pmid">28592202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kr&#x000e1;sensk&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].</article-title>
            <source>Klin Onkol</source>
            <year>2016</year>
            <season>Fall</season>
            <volume>29 Suppl 3</volume>
            <fpage>S39</fpage>
            <page-range>S39-49</page-range>
            <pub-id pub-id-type="pmid">28118723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foglietta</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Inno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Iuliis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Duranti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turazza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tarantini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gori</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients.</article-title>
            <source>Clin Breast Cancer</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-17</page-range>
            <pub-id pub-id-type="pmid">27561703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burstein</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Aromatase inhibitor-associated arthralgia syndrome.</article-title>
            <source>Breast</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-34</page-range>
            <pub-id pub-id-type="pmid">17368903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiboni</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Ponzano</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Fetal safety profile of aromatase inhibitors: Animal data.</article-title>
            <source>Reprod Toxicol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>66</volume>
            <fpage>84</fpage>
            <page-range>84-92</page-range>
            <pub-id pub-id-type="pmid">27697604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Poznak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Makris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clack</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barlow</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Eastell</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Lipid profiles within the SABRE trial of anastrozole with and without risedronate.</article-title>
            <source>Breast Cancer Res Treat</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>134</volume>
            <issue>3</issue>
            <fpage>1141</fpage>
            <page-range>1141-7</page-range>
            <pub-id pub-id-type="pmid">22763465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonnelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Petrioli</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer.</article-title>
            <source>Clin Interv Aging</source>
            <year>2008</year>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>647</fpage>
            <page-range>647-57</page-range>
            <pub-id pub-id-type="pmid">19281057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-74657.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jonat</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blomqvist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eiermann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Winblad</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tyrrell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mauriac</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Roche</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lundgren</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hellmund</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Azab</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.</article-title>
            <source>Eur J Cancer</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>32A</volume>
            <issue>3</issue>
            <fpage>404</fpage>
            <page-range>404-12</page-range>
            <pub-id pub-id-type="pmid">8814682</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
